Latest Insider Transactions at Bridge Bio Pharma, Inc. (BBIO)
This section provides a real-time view of insider transactions for Bridge Bio Pharma, Inc. (BBIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BridgeBio Pharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BridgeBio Pharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 11
2025
|
Charles J Homcy |
SELL
Open market or private sale
|
Direct |
50,000
-5.17%
|
$2,400,000
$48.0 P/Share
|
|
Aug 08
2025
|
Charles J Homcy |
SELL
Open market or private sale
|
Direct |
250,000
-10.72%
|
$11,500,000
$46.25 P/Share
|
|
Aug 08
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.64%
|
$1,840,000
$46.3 P/Share
|
|
Aug 07
2025
|
Maricel Apuli Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,000
-0.7%
|
$45,000
$45.44 P/Share
|
|
Aug 07
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.63%
|
$1,800,000
$45.37 P/Share
|
|
Aug 05
2025
|
Andrea Ellis |
SELL
Open market or private sale
|
Direct |
17,167
-48.01%
|
$841,183
$49.0 P/Share
|
|
Aug 05
2025
|
Andrea Ellis |
BUY
Exercise of conversion of derivative security
|
Direct |
17,167
+32.44%
|
$274,672
$16.75 P/Share
|
|
Jul 02
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-1.23%
|
$1,680,000
$42.73 P/Share
|
|
Jul 01
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
40,000
-0.61%
|
$1,680,000
$42.7 P/Share
|
|
Jun 27
2025
|
Viking Global Investors LP |
SELL
Open market or private sale
|
Indirect |
3,500,000
-15.87%
|
$154,000,000
$44.0 P/Share
|
|
Jun 27
2025
|
Charles J Homcy |
SELL
Bona fide gift
|
Direct |
20,000
-1.62%
|
-
|
|
Jun 26
2025
|
Hannah Valantine |
SELL
Open market or private sale
|
Indirect |
2,289
-48.71%
|
$100,716
$44.08 P/Share
|
|
Jun 26
2025
|
Hannah Valantine |
SELL
Open market or private sale
|
Direct |
2,418
-12.99%
|
$106,392
$44.06 P/Share
|
|
Jun 24
2025
|
Frank Mccormick |
SELL
Open market or private sale
|
Indirect |
100,000
-10.2%
|
$4,400,000
$44.23 P/Share
|
|
Jun 20
2025
|
Jennifer E. Cook |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+32.41%
|
-
|
|
Jun 20
2025
|
Andrea Ellis |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+26.17%
|
-
|
|
Jun 20
2025
|
Andrew Lo |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+10.75%
|
-
|
|
Jun 20
2025
|
Ali J. Satvat |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+3.82%
|
-
|
|
Jun 20
2025
|
Ronald J Daniels |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+27.94%
|
-
|
|
Jun 20
2025
|
Eric Aguiar |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+50.0%
|
-
|
|
Jun 20
2025
|
Frank Mccormick |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+98.76%
|
-
|
|
Jun 20
2025
|
Hannah Valantine |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+44.1%
|
-
|
|
Jun 20
2025
|
Douglas A. Dachille |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+50.0%
|
-
|
|
Jun 20
2025
|
Fred Hassan |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+20.29%
|
-
|
|
Jun 20
2025
|
Charles J Homcy |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+0.53%
|
-
|
|
Jun 20
2025
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+6.48%
|
-
|
|
Jun 20
2025
|
Randal W. Scott |
BUY
Grant, award, or other acquisition
|
Direct |
6,589
+36.25%
|
-
|
|
Jun 10
2025
|
Hannah Valantine |
SELL
Open market or private sale
|
Direct |
4,292
-70.87%
|
$171,680
$40.0 P/Share
|
|
Jun 10
2025
|
Hannah Valantine |
BUY
Exercise of conversion of derivative security
|
Direct |
4,292
+41.48%
|
$68,672
$16.75 P/Share
|
|
May 20
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
75,000
-1.54%
|
$2,475,000
$33.4 P/Share
|
|
May 19
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,156
-5.38%
|
$863,148
$33.54 P/Share
|
|
May 16
2025
|
Neil Kumar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,854
-11.89%
|
$1,084,182
$33.84 P/Share
|
|
May 16
2025
|
Neil Kumar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
64,696
+18.97%
|
-
|
|
May 16
2025
|
Maricel Apuli Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,780
-3.24%
|
$157,740
$33.84 P/Share
|
|
May 16
2025
|
Thomas Trimarchi President and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,317
-4.07%
|
$703,461
$33.84 P/Share
|
|
May 12
2025
|
Kkr Genetic Disorder L.P. |
SELL
Open market or private sale
|
Indirect |
6,000,000
-31.15%
|
$204,000,000
$34.2 P/Share
|
|
May 08
2025
|
Frank Mccormick |
SELL
Bona fide gift
|
Direct |
3,000
-3.76%
|
-
|
|
May 07
2025
|
Frank Mccormick |
SELL
Bona fide gift
|
Direct |
33,000
-29.28%
|
-
|
|
May 02
2025
|
Maricel Apuli Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,026
-0.69%
|
$38,988
$38.51 P/Share
|
|
May 02
2025
|
Andrew Lo |
SELL
Open market or private sale
|
Indirect |
100,000
-48.64%
|
$3,800,000
$38.5 P/Share
|
|
Apr 22
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
75,000
-1.52%
|
$2,550,000
$34.11 P/Share
|
|
Apr 14
2025
|
Andrea Ellis |
SELL
Open market or private sale
|
Direct |
10,000
-45.45%
|
$350,000
$35.0 P/Share
|
|
Apr 14
2025
|
Andrea Ellis |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+31.25%
|
$80,000
$8.45 P/Share
|
|
Apr 01
2025
|
Andrea Ellis |
SELL
Open market or private sale
|
Direct |
30,000
-71.43%
|
$1,020,000
$34.05 P/Share
|
|
Apr 01
2025
|
Andrea Ellis |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+41.67%
|
$240,000
$8.45 P/Share
|
|
Mar 25
2025
|
Neil Kumar Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
75,000
-1.49%
|
$2,700,000
$36.87 P/Share
|
|
Mar 19
2025
|
Thomas Trimarchi President and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
109,100
+17.25%
|
-
|
|
Mar 19
2025
|
Maricel Apuli Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,660
+13.73%
|
-
|
|
Mar 06
2025
|
Hannah Valantine |
SELL
Open market or private sale
|
Direct |
12,875
-87.95%
|
$412,000
$32.58 P/Share
|
|
Mar 06
2025
|
Hannah Valantine |
BUY
Exercise of conversion of derivative security
|
Direct |
12,875
+46.79%
|
$206,000
$16.75 P/Share
|